Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review

Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy of bosut...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., Apperley, Jane F., DeAngelo, Daniel J., Deininger, Michael W., Kota, Vamsi K., Rousselot, Philippe, Gambacorti-Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307238/
https://www.ncbi.nlm.nih.gov/pubmed/30587215
http://dx.doi.org/10.1186/s13045-018-0685-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307238/
https://www.ncbi.nlm.nih.gov/pubmed/30587215
http://dx.doi.org/10.1186/s13045-018-0685-2

Ejemplares similares